

Supplementary Materials

Real-World Use of Ubrogepant as Acute Treatment for Migraine With an Anti-Calcitonin Gene–Related Peptide Monoclonal Antibody: Results From COURAGE

Richard B. Lipton MD¹ Janette Contreras-De Lama PhD² Daniel Serrano PhD^{3*} Ella Engstrom BS^{3*} Nicolai D. Ayasse PhD^{3*} Weijie Poh PhD^{4*} François Cadiou MBA⁴ Aubrey Manack Adams PhD²

¹Albert Einstein College of Medicine, Bronx, NY, USA; ²AbbVie, Irvine, CA, USA; ³OPEN Health, Bethesda, MD, USA; ⁴Healint Pte Ltd, Singapore, Singapore

*At the time of study conduct.

Corresponding Author:

Aubrey Manack Adams
aubrey.adams@abbvie.com

Supplementary Table S1. Number of treated attacks in ubrogepant and anti-CGRP mAb group (n=245)^a

Treated Attacks During Study Period	Number of Participants
1	245
2	220
3	188
4	142
5	108
6	85
7	62
8	44
9	33
10	26

Abbreviations: CGRP, calcitonin gene–related peptide; mAb, monoclonal antibody.


^aIncluded participants who used an anti-CGRP mAb without onabotulinumtoxinA for current preventive treatment.

Supplementary Table S2. Number of treated attacks in ubrogepant, anti-CGRP mAb, and onabotulinumtoxinA group (n=69)

Treated Attacks During Study Period	Number of Participants
1	69
2	65
3	54
4	45
5	35
6	26
7	20
8	15
9	11
10	7

Abbreviations: CGRP, calcitonin gene–related peptide; mAb, monoclonal antibody.


Supplementary Figure S1. Ubrogapant and anti-CGRP mAb group^a: proportion of participants achieving meaningful pain relief across up to 10 treated attacks.



Abbreviations: CGRP, calcitonin gene-related peptide; mAb, monoclonal antibody; MPR, meaningful pain relief.

^aIncluded participants who used an anti-CGRP mAb without onabotulinumtoxinA for current preventive treatment.


Supplementary Figure S2. Ubrogapant and anti-CGRP mAb group^a: proportion of participants achieving return to normal function across up to 10 treated attacks.



Abbreviations: CGRP, calcitonin gene-related peptide; mAb, monoclonal antibody; RNF, return to normal function.


^aIncluded participants who used an anti-CGRP mAb without onabotulinumtoxinA for current preventive treatment.

Supplementary Figure S3. Ubrogapant, anti-CGRP mAb, and onabotulinumtoxinA group: proportion of participants achieving meaningful pain relief across up to 10 treated attacks.



Abbreviations: CGRP, calcitonin gene-related peptide; mAb, monoclonal antibody; MPR, meaningful pain relief.

Supplementary Figure S4. Ubrogapant, anti-CGRP mAb, and onabotulinumtoxinA group: proportion of participants achieving return to normal function across up to 10 treated attacks.



Abbreviations: CGRP, calcitonin gene-related peptide; mAb, monoclonal antibody; RNF, return to normal function.